Pava Partners advised the founders and shareholders of Synaptikon GmbH (“Synaptikon”), the company behind the Digital Health Application NeuroNation MED and the NeuroNation brand, on a strategic investment by the Schwabe Group (“Schwabe”).

With over 30 million users worldwide, Synaptikon is one of the leading providers of digital cognitive interventions. The NeuroNation MED app is permanently approved as a Digital Health Application (DiGA) and can be prescribed by physicians and psychotherapists.

Synaptikon on Pava Partners

“The Pava team was always extremely well prepared, consistent, and goal-oriented – before, during, and after the process. This is our second transaction with Kevin Kissner and his team, and it certainly won’t be our last. On behalf of all stakeholders, I would like to thank Kevin and the team at Pava Partners. Thanks to their outstanding market expertise, excellent network, and structured process management, we have found the ideal strategic partner for the next phase of growth in the Schwabe Group, even in a highly competitive process,” says Jakob Futorjanski, Co-founder and CEO of Synaptikon.